A BCMA bispecific antibody for myeloma
Teclistamab
A targeted immune treatment for advanced myeloma that brings the body's T cells to attack cancer cells.
What is Teclistamab?
Teclistamab is a specialist treatment for advanced myeloma, a cancer of the bone marrow. It is a bispecific antibody that links a myeloma cell marker (BCMA) to the body's own immune T cells, bringing them together so the T cells attack the cancer. The two most important risks are cytokine release syndrome (a strong immune reaction causing fever, low blood pressure and breathing problems) and neurological problems (sometimes called ICANS), such as confusion or difficulty speaking. Because of these, treatment is started with small step-up doses in hospital with close monitoring. Serious infections and low blood counts are also important, so infection-prevention medicines are usually given. It can harm a developing baby, so reliable contraception is essential.
Education and reference only. This is a plain-language guide to Teclistamab — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Teclistamab is a specialist cancer medicine used to treat myeloma, a cancer of plasma cells in the bone marrow, when several earlier treatments have already been tried. It is a bispecific antibody, meaning it grabs hold of two things at once: a marker called BCMA on myeloma cells, and a marker called CD3 on the body's immune T cells. By bringing them together, it directs the T cells to attack and kill the myeloma cells. It is given as an injection under the skin, started with smaller step-up doses in hospital, then continued at a regular dose under close specialist supervision.
How it works
Teclistamab has two arms. One attaches to BCMA, a marker found on myeloma cells, and the other attaches to CD3 on the body's T cells, which are immune cells that can kill abnormal cells. By holding a myeloma cell and a T cell close together, it activates the T cell to destroy the myeloma cell. This strong activation of the immune system is what makes it effective, but it is also why it can trigger cytokine release syndrome and effects on the nervous system, particularly when treatment is first ramped up. For this reason the first doses are given gradually (a step-up schedule) in hospital with careful monitoring.
Company & origin
Originated / developed by: Specialist manufacturer.
A specialist cancer treatment used in the UK for advanced myeloma, started in hospital because of the risk of cytokine release syndrome.
Practical use
How to take Teclistamab
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- It is given as an injection under the skin, starting with smaller step-up doses in hospital with close monitoring.
- Report fever, chills, a fast heartbeat, dizziness or breathing difficulty straight away, as these can signal cytokine release syndrome.
- You and those close to you should watch for confusion, drowsiness, difficulty speaking or tremor, and report them at once.
- Take the infection-prevention medicines you are given and report any high temperature or feeling unwell urgently.
- Use reliable contraception during treatment and for the time your team advises, as it can harm a developing baby, and follow advice about not driving early on.
Weighing it up
Advantages & disadvantages of Teclistamab
Advantages
- A targeted immune treatment that directs the body's T cells to attack myeloma cells.
- An option for advanced myeloma after several other treatments have been tried.
- Given as an injection under the skin once the early step-up phase is complete.
Disadvantages
- Can cause cytokine release syndrome, a strong immune reaction needing hospital monitoring at the start.
- Can cause nervous-system problems such as confusion or difficulty speaking.
- Lowers the immune system, raising the risk of serious infection, and commonly lowers blood counts.
Practical use
Good to know
The two effects to understand most are cytokine release syndrome and nervous-system problems. Cytokine release syndrome is a strong immune reaction that can cause fever, chills, a fast heartbeat, low blood pressure and breathing difficulty; it is most likely during the early step-up doses, which is why these are given in hospital with close monitoring and medicines such as tocilizumab ready to treat it. Neurological problems, sometimes called ICANS, can include confusion, drowsiness, difficulty speaking, tremor or, rarely, seizures; you and those around you are asked to watch for and report these. Serious infections are common because the treatment lowers the immune system, so infection-prevention medicines and sometimes antibody (immunoglobulin) replacement are used, and any high temperature must be reported urgently. A drop in blood cells is also common. It can harm a developing baby, so reliable contraception is essential. You may be advised not to drive for a period after starting because of the risk of neurological effects.
Who should not take it / use with caution
- People who have had a serious allergic reaction to teclistamab should not receive it.
- It must not be used in pregnancy because it can seriously harm a developing baby.
- It is used with great care, and only in suitable hospital settings, in people with active serious infection or certain nervous-system conditions, under specialist guidance.
Monitoring
- Close hospital monitoring during the step-up doses for cytokine release syndrome and nervous-system effects.
- Regular blood tests for blood counts and antibody levels, with infection monitoring throughout.
- Ongoing review of side effects and how the myeloma is responding.
Side effects
- Cytokine release syndrome, with fever, chills, low blood pressure and breathing difficulty.
- Nervous-system problems such as confusion, drowsiness, difficulty speaking or tremor.
- Serious infections, because the treatment lowers the immune system.
- A drop in infection-fighting white cells, platelets and red cells, plus tiredness.
Key interactions
- Tell your team about all your medicines, as some affect the immune system or add to infection risk.
- At the start of treatment, some other medicines may be paused or timed carefully around the step-up doses.
- Live vaccines are generally avoided during treatment; check with your team before any vaccination.
Available as: A solution given as an injection under the skin, started in hospital.
Answers
Teclistamab: frequently asked questions
What is teclistamab used for?
It is used to treat advanced myeloma, a cancer of the bone marrow, by bringing the body's immune T cells together with myeloma cells so the T cells attack them.
Why is it started in hospital?
The early step-up doses can trigger cytokine release syndrome and nervous-system effects, so they are given in hospital with close monitoring and treatments ready.
What is cytokine release syndrome?
It is a strong immune reaction that can cause fever, chills, a fast heartbeat, low blood pressure and breathing difficulty; report these symptoms straight away.
Why do I need infection-prevention medicines?
The treatment lowers the immune system, so serious infections can occur; preventive medicines and sometimes antibody replacement are used, and any high temperature must be reported urgently.
Can I drive after starting it?
You may be advised not to drive for a period after starting, because of the risk of confusion or other nervous-system effects.
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.